Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells
About:Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed AML donors. AML is diagnosed and staged by marrow myeloblast percentage, making marrow the essential specimen for diagnosis, risk stratification, and MRD monitoring. Ideal for FLT3/NPM1 molecular studies, blast immunophenotyping, and targeted therapy research. Stratification by cytogenetic/molecular risk group and treatment phase.
About Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells
Acute Myeloid Leukemia (AML) Bone Marrow Mononuclear Cells for Leukemia Research
Acute myeloid leukemia (AML) bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with AML — an aggressive myeloid malignancy defined by marrow blast accumulation.
AML Biology and Why Bone Marrow
- AML diagnosis requires a marrow myeloblast count of 20% or greater (per WHO criteria), making bone marrow aspirate the required diagnostic specimen rather than peripheral blood, which may not reflect true marrow blast burden.
- Cytogenetic and molecular risk stratification – including FLT3-ITD, NPM1, CEBPA, and TP53 status – is performed on marrow aspirate and directly informs treatment intensity and eligibility for targeted therapies.
- Minimal residual disease (MRD) assessment by flow cytometry or molecular methods on post-treatment marrow is a key determinant of relapse risk and consolidation strategy.
- Targeted agents including FLT3 inhibitors, IDH1/2 inhibitors, and venetoclax-based regimens have made marrow-derived blast material essential for pharmacodynamic and resistance-mechanism studies.
- Marrow stromal and microenvironment interactions are an active area of research into AML chemoresistance and relapse.
Donor Stratification Available
- Cytogenetic and molecular risk group (favorable, intermediate, adverse)
- Key mutation status where documented: FLT3, NPM1, CEBPA, TP53, IDH1/2
- Disease phase: newly diagnosed, post-induction, relapsed/refractory
- Blast percentage at collection where available
- Treatment history, including targeted agents or stem cell transplant
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed AML donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- AML diagnosis confirmation and cytogenetic/molecular subtype where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history and disease phase where documented
- Additional AML-specific metadata available on request
Applications
- Minimal residual disease (MRD) detection and monitoring assay development
- FLT3, NPM1, and other molecular marker studies
- Targeted therapy pharmacodynamic and resistance-mechanism research
- Blast immunophenotyping studies
- Marrow microenvironment and chemoresistance research
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection, and our MDS BMMCs for progression-to-AML studies.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
AML BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.